![](/img/cover-not-exists.png)
TREATMENT WITH THE CHIMERIC ANTI-IL-2Rα ANTIBODY BASILIXIMAB (SIMULECT®) AFFECTS BOTH THE IL-2 AND THE IL-15 SIGNALING PATHWAY AFTER CLINICAL KIDNEY TRANSPLANTATION.
Baan, Carla C., Riemsdijk, Iza C. van, Haperen, Maud J.A.M. Boelaars-van, IJzermans, Jan N.M., Weimar, WillemVolume:
69
Journal:
Transplantation
DOI:
10.1097/00007890-200004271-00570
Date:
April, 2000
File:
PDF, 731 KB
2000